

4.0.3 DOC Cmte minutes

Dementia (update) Guideline Committee meeting 4 – development

Date: 04/02/2016

Location: NICE offices, Manchester

Minutes: Final

NICE National Institute for
Health and Care Excellence

Committee members present:		
Damien Longson (Chair)		(Present for notes 1–8)
Louise Allan (LA)		(Present for notes 1–8)
Linda Clare (LC)		(Present for notes 2–8)
Richard Clibbens (RC)		(Present for notes 5–8)
Carol Duff (CD)		(Present for notes 5–8)
Paul Dunnery (PD)		(Present for notes 5–8)
Sandra Evans (SA)		(Present for notes 1–8)
Karen Harrison-Dening (KHD)		(Present for notes 5–8)
Hannah Luff (HL)		(Present for notes 1–8)
Kevin Minier (KMin)		(Present for notes 1–8)
John O'Brien (JO)		(Present for notes 1–8)
Ruth O'Dea (RO)		(Present for notes 1–8)
Chris Roberts (CR)		(Present for notes 1–8)
Louise Robinson (LR)		(Present for notes 1–8)
Joanne Brady (JB)		(Present for notes 1–8)
Jeremy Isaacs (JI)		(Present for notes 1–8)
Catherine Pascoe (CP)		(Present for notes 1–8)

In attendance:		
Vicky Gillis (VG)	ICG – Technical Analyst	(Present for notes 1–8)
Steven Ward (SW)	ICG – Health Economist	(Present for notes 1–8)
Sue Spiers (SS)	ICG – Associate Director	(Present for notes 1–7)
Gabriel Rogers (GR)	ICG – Technical Advisor (HE)	(Present for notes 1–8)
Joshua Pink (JP)	ICG – Technical Advisor	(Present for notes 1–8)
Harry Allen (HA)	ICG – Expert Advisor	(Present for notes 1–8)
Holly Irwin (HI)	ICG – Project Manager	(Present for notes 1–8)
Angela Parkin (AP)	NICE Medicines Advisor	(Present for notes 1–8)
Elizabeth Barrett (EB)	NICE Information Specialist	(Present for notes 1–8)
Jeremy Wight (JW)	NICE Clinical Advisor	(Present for notes 1–8)

4.0.3 DOC Cmte minutes

Observers:	
Jayne Roberts	Accompanying lay member

Apologies:	
Kate Mitchell	Committee member
Sarah Partington	Committee member
Tracey Wright	Committee member
Rupert Franklin	NICE Guideline Commissioning Manager

1. Welcome, objectives for the meeting, Dols and minutes of previous meeting

The Chair welcomed the Committee members and attendees to the fourth meeting of the dementia (update) guideline committee. The Committee members and attendees introduced themselves. In particular the Chair welcomed JP as the new ICG Technical Advisor and Jeremy Wight as NICE Clinical Advisor.

Apologies for the meeting were received as detailed above.

The Chair outlined the proposed objectives of the meeting, which included:

- To receive updates on outstanding issues discussed at the previous meeting
- To discuss and agree draft review questions not discussed at the previous meeting
- To discuss and agree a number of review protocols
- To have a discussion regarding prioritisation for health economic modelling

The declarations of interest (DoI) register was made available to the Chair. The Chair requested that committee members and attendees outline any existing potential conflicts of interest relevant to the objectives of this meeting, or any new potential conflicts of interest.

No new interests were declared.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

2. Update on the inclusion of co-prescribing within the pharmacological management of Alzheimer's Disease

4.0.3 DOC Cmte minutes

The Chair introduced GR, who provided an update on co-prescribing of acetylcholinesterase inhibitors (AChEIs) and memantine in Alzheimer's Disease in line with the existing Technology Appraisal guidance.

Action: the committee to be kept informed of progress with this issue over future committee meetings.

3. Review question 1 accelerated process update

The Chair introduced VG who presented an update on the final (post edit) version of the review question (RQ) recommendations and outlined the timeline for consultation, feedback and publication. The Chair thanked VG for her presentation.

4. Draft review questions

The Chair introduced SS who informed the committee that the large number of draft review questions currently proposed for the guideline could have a significant impact on the development time for the guideline and that it was important not only that the guideline adequately covers the agreed scope but that it is published within a reasonable time frame to ensure its clinical validity. SS advised the committee that further internal discussions will take place within NICE to assess likely development time available to undertake the guideline and that this may involve an exercise to prioritise areas currently covered by the draft review questions. SS clarified that any decisions around inclusion /exclusion of review questions would be discussed with the committee.

VG presented the review questions that were not discussed at the previous committee meeting. The committee suggested a number of amendments to the draft review questions.

Action: HI to circulate an amended list of draft review questions to the committee.

5. Discussion and agreement of review protocols

The committee considered and agreed review protocols for the following review questions:

RQ30 – 'Are there effective methods for assessing intercurrent illness in people living with dementia that are different from those already in use for those who do not have dementia?'

RQ31 – 'Are there effective methods for treating intercurrent illness in people living with dementia that are different from those already in use for those who do not have dementia?'

RQ32 – 'Are there effective methods for treating people with dementia with co-existing long term conditions that are different from those already in use for those who do not have dementia?'

RQ33 – 'Are there effective ways of treating comorbid psychiatric illness in people living with dementia that are different from those already in use for those who do not have dementia?' the committee agreed a change of wording for RQ33 to more accurately represent the context in which psychiatric comorbidities are to be considered.

Actions: HI to circulate a copy of the final draft review protocols agreed in the meeting. HI to

4.0.3 DOC Cmte minutes

circulate a copy of the review protocol for the pharmacological treatment of Dementia with Lewy Bodies to the committee.

6. Health economic prioritisation

The Chair introduced SW for a discussion about health economic prioritisation. SW provided a recap around the basic principles of health economics and included an update about a planned change to the NICE guideline manual to clarify underlying principles for recommendations with potential resource impact. The committee discussed a range of possible priority areas of the guideline for health economic modelling. The Chair thanked SW for his presentation.

7. Prioritisation of review questions

The Chair facilitated a structured group work session to start to explore relative priorities and thematic links within the full set of draft review questions. He explained that the outputs from this group work would be discussed with the committee further at the next committee meeting.

8. Next steps

HI highlighted a number of key dates for consultation and publication of review question 1 and reminded the committee of the date and location of the next meeting.

The Chair informed the committee that HI would be shortly be starting a new role within NICE and he wished her well in this role. HI outlined the cover arrangements until her permanent replacement started in post.

Date of next meeting: Thursday 17th March 2016

Location of next meeting: NICE offices, London